SCHEMBL31664583

SCHEMBL31664583

CCc1c(-c2ccccc2N)c(=O)n2nc(C)nc2n1CC(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.41
▸ TP53 P04637 1/20 0.41
▸ AKR1B1 P15121 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.39
▸ FPR1 P21462 1/20 0.39
▸ FPR2 P25090 1/20 0.39
▸ PTGS1 P23219 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ TRPA1 O75762 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ BCHE P06276 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31713890 0.89 MAPT (0.39) MAPTTP53AKR1B1KDM4EFPR1
SCHEMBL31713931 0.86 MAPT (0.39) MAPTAKR1B1KDM4EFPR1FPR2
SCHEMBL31678803 0.85 MAPT (0.39) MAPTTP53AKR1B1KDM4EFPR1
SCHEMBL31664558 0.85 AKR1B1 (0.42) MAPTTP53AKR1B1KDM4EFPR1
SCHEMBL31664550 0.85 AKR1B1 (0.42) MAPTTP53AKR1B1KDM4EFPR1
SCHEMBL31678252 0.84 KDM4E (0.40) MAPTTP53AKR1B1KDM4EFPR1
SCHEMBL31713832 0.83 WRN (0.49) MAPTTP53AKR1B1KDM4ELMNA
SCHEMBL31664578 0.83 KDM4E (0.43) MAPTTP53AKR1B1KDM4EFPR1
SCHEMBL31678841 0.83 MAPT (0.39) MAPTTP53AKR1B1KDM4ELMNA
SCHEMBL31713755 0.80 AKR1B1 (0.40) MAPTTP53AKR1B1KDM4EFPR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236622-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN INCYTE CORPORATION (US) 2025-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236622-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF WRN WRN, BLM, RECQL MAPT 4634/4885TP53 16/4885AKR1B1 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback